Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
Andreina Baj, Federica Novazzi, Renée Pasciuta, Angelo Genoni, Francesca Drago Ferrante, Marilena Valli, Michele Partenope, Rosalia Tripiciano, Andrea Ciserchia, Giuseppe Catanoso, Daniele Focosi, Fabrizio Maggi
Abstract
CI 31.2-45.9 days) for Alpha variant, 6.9 days (95% CI 3.2-10.6 days) for Beta, and 12.3 days (95% CI 6.8-17.8 days) for Delta (Table). These data indicate the possibility that SARS-CoV-2 variants are able to escape humoral induced by wild-type prototype inactivated vaccines, which is consistent with results of other recent studies (4,5). Our findings support administering vaccine boosters, especially where these variants circulate.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyDeltaMutation2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)CoronavirusMedicineBiologyOutbreakGeneticsDiseaseGeneInfectious disease (medical specialty)Internal medicineEngineeringAerospace engineeringSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies